Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Severe Bleeding in HHT
NCT03227263Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by Hospices Civils de Lyon. Started Sep 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT03227263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227263.